Carna Biosciences Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-2,173	-1,130	-1,323	-532	-1,102
Depreciation & Amortization	31	35	33	19	12
Loss (Gain) From Sale of Assets	93	4	44	9	26
Other Operating Activities	-18	-35	-16	49	-135
Change in Accounts Receivable	704	-599	1,069	-1,110	-13
Change in Inventory	-14	-21	-8	-5	-5
Change in Accounts Payable	-38	-44	-73	-20	70
Change in Other Net Operating Assets	41	113	-434	54	-113
Operating Cash Flow	-1,374	-1,677	-708	-1,536	-1,260
Capital Expenditures	-13	-11	-126	-41	-64
Sale (Purchase) of Intangibles	-	-	-	-	-4
Other Investing Activities	-	-	1	-	-2
Investing Cash Flow	-13	-11	-125	-41	-70
Long-Term Debt Issued	-	-	-	300	-
Long-Term Debt Repaid	-120	-151	-239	-190	-298
Net Debt Issued (Repaid)	-120	-151	-239	110	-298
Issuance of Common Stock	694	1,343	606	957	1,023
Other Financing Activities	-7	-10	-	-3	-1
Financing Cash Flow	567	1,182	367	1,064	724
Foreign Exchange Rate Adjustments	39	16	28	31	-8
Miscellaneous Cash Flow Adjustments	1	1	-	1	-1
Net Cash Flow	-780	-489	-438	-481	-615
Free Cash Flow	-1,387	-1,688	-834	-1,577	-1,324
Free Cash Flow Margin	-218.08%	-103.88%	-60.17%	-78.19%	-116.86%
Free Cash Flow Per Share	-77.44	-100.48	-61.24	-124.22	-107.65
Cash Interest Paid	2	3	5	4	7
Cash Income Tax Paid	18	33	18	-40	135
Levered Free Cash Flow	-662.38	-1,290	-364.5	-1,451	-990
Unlevered Free Cash Flow	-660.5	-1,287	-360.75	-1,449	-985.63
Change in Working Capital	693	-551	554	-1,081	-61

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.